Dimachkie, M. M., Barohn, R. J., Byrne, B., Goker-Alpan, O., Kishnani, P. S., Ladha, S., … Benedikt Schoser; on behalf of NEO-EXT investigators, . (2021). NEO1/NEO-EXT studies: Safety and exploratory efficacy of repeat avalglucosidase alfa dosing after up to 6 years in participants with late-onset pompe disease (LOPD). In Molecular Genetics and Metabolism (Vol. 132, pp. S34–S34). Elsevier BV. https://doi.org/10.1016/j.ymgme.2020.12.064

Dimachkie, Mazen M., Richard J. Barohn, Barry Byrne, Ozlem Goker-Alpan, Priya S. Kishnani, Shafeeq Ladha, Pascal Laforêt, et al. “NEO1/NEO-EXT studies: Safety and exploratory efficacy of repeat avalglucosidase alfa dosing after up to 6 years in participants with late-onset pompe disease (LOPD).” In Molecular Genetics and Metabolism, 132:S34–S34. Elsevier BV, 2021. https://doi.org/10.1016/j.ymgme.2020.12.064.

Dimachkie MM, Barohn RJ, Byrne B, Goker-Alpan O, Kishnani PS, Ladha S, et al. NEO1/NEO-EXT studies: Safety and exploratory efficacy of repeat avalglucosidase alfa dosing after up to 6 years in participants with late-onset pompe disease (LOPD). In: Molecular Genetics and Metabolism. Elsevier BV; 2021. p. S34–S34.

Dimachkie, Mazen M., et al. “NEO1/NEO-EXT studies: Safety and exploratory efficacy of repeat avalglucosidase alfa dosing after up to 6 years in participants with late-onset pompe disease (LOPD).” Molecular Genetics and Metabolism, vol. 132, no. 2, Elsevier BV, 2021, pp. S34–S34. Crossref, doi:10.1016/j.ymgme.2020.12.064.

Dimachkie MM, Barohn RJ, Byrne B, Goker-Alpan O, Kishnani PS, Ladha S, Laforêt P, Mengel KE, Pena LDM, Sacconi S, Straub V, Trivedi J, Van Damme P, van der Ploeg A, Vissing J, Young P, Haack KA, Ivanina I, Lu X, Benedikt Schoser; on behalf of NEO-EXT investigators. NEO1/NEO-EXT studies: Safety and exploratory efficacy of repeat avalglucosidase alfa dosing after up to 6 years in participants with late-onset pompe disease (LOPD). Molecular Genetics and Metabolism. Elsevier BV; 2021. p. S34–S34.